Literature DB >> 3786273

A point-source epidemic of leptospirosis. Description of cases, cause, and prevention.

T R Jevon, M P Knudson, P A Smith, P S Whitecar, R L Blake.   

Abstract

Leptospirosis is a zoonotic disease that consists of fever, headache, myalgias, and multiple organ involvement, has varying clinical severity and morbidity, and can occur in epidemic form. Diagnosis is based on culture or serologic demonstration of recent infection. There is evidence that doxycycline therapy started early in the course of the disease favorably affects duration and severity. Antibiotic therapy is often initiated because of a strong suspicion of the disease, before bacteriologic or serologic confirmation of the diagnosis is completed. Public health measures play an important role in minimizing the incidence of leptospirosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3786273     DOI: 10.1080/00325481.1986.11699636

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  5 in total

Review 1.  Leptospirosis.

Authors:  P N Levett
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

2.  Leptospirosis, water sports, and chemoprophylaxis.

Authors:  David A Haake; Manjula Dundoo; Rumi Cader; Bernard M Kubak; Rudy A Hartskeerl; James J Sejvar; David A Ashford
Journal:  Clin Infect Dis       Date:  2002-04-04       Impact factor: 9.079

3.  Antibiotics for Travelers: What's Good and What's Not.

Authors:  Kathryn N. Suh; Jay S. Keystone
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

Review 4.  Leptospirosis in humans.

Authors:  David A Haake; Paul N Levett
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

5.  Cluster of Leptospirosis Acquired Through River Surfing in Switzerland.

Authors:  Peter W Schreiber; Leonardo Aceto; Raphael Korach; Nelson Marreros; Marie-Pierre Ryser-Degiorgis; Huldrych F Günthard
Journal:  Open Forum Infect Dis       Date:  2015-07-07       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.